COVID-19 Impact on Global Lysosomal Disease Treatment Market Size, Status and Forecast 2020-2026

August 2020 | 90 pages | ID: CF84B2EE0E35EN
QYResearch

Abstracts

This report focuses on the global Lysosomal Disease Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Lysosomal Disease Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Astellas Pharma
• Astrazeneca
• Actelion Pharmaceuticals Ltd.
• Eli Lilly and Co.
• Merck & Co.
• Novo Nordisk A/S
• Shire
• Pfizer
• Sanofi
• BioMarin

Market segment by Type, the product can be split into

• Hematopoietic Stem Cell Transplantation
• Enzyme Replacement Therapy
• Substrate Reduction
• Chaperone Therapies

Market segment by Application, split into

• Hospitals
• Clinics
• Stem Cell Transplant Center
• Research Organizations
• Others

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Lysosomal Disease Treatment status, future forecast, growth opportunity, key market and key players.
• To present the Lysosomal Disease Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Lysosomal Disease Treatment are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Lysosomal Disease Treatment Revenue
1.4 Market Analysis by Type
  1.4.1 Global Lysosomal Disease Treatment Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Hematopoietic Stem Cell Transplantation
  1.4.3 Enzyme Replacement Therapy
  1.4.4 Substrate Reduction
  1.4.5 Chaperone Therapies
1.5 Market by Application
  1.5.1 Global Lysosomal Disease Treatment Market Share by Application: 2020 VS 2026
  1.5.2 Hospitals
  1.5.3 Clinics
  1.5.4 Stem Cell Transplant Center
  1.5.5 Research Organizations
  1.5.6 Others
1.6 Coronavirus Disease 2019 (Covid-19): Lysosomal Disease Treatment Industry Impact
  1.6.1 How the Covid-19 is Affecting the Lysosomal Disease Treatment Industry
    1.6.1.1 Lysosomal Disease Treatment Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Lysosomal Disease Treatment Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Lysosomal Disease Treatment Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Lysosomal Disease Treatment Market Perspective (2015-2026)
2.2 Lysosomal Disease Treatment Growth Trends by Regions
  2.2.1 Lysosomal Disease Treatment Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Lysosomal Disease Treatment Historic Market Share by Regions (2015-2020)
  2.2.3 Lysosomal Disease Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Lysosomal Disease Treatment Market Growth Strategy
  2.3.6 Primary Interviews with Key Lysosomal Disease Treatment Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Lysosomal Disease Treatment Players by Market Size
  3.1.1 Global Top Lysosomal Disease Treatment Players by Revenue (2015-2020)
  3.1.2 Global Lysosomal Disease Treatment Revenue Market Share by Players (2015-2020)
  3.1.3 Global Lysosomal Disease Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Lysosomal Disease Treatment Market Concentration Ratio
  3.2.1 Global Lysosomal Disease Treatment Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Lysosomal Disease Treatment Revenue in 2019
3.3 Lysosomal Disease Treatment Key Players Head office and Area Served
3.4 Key Players Lysosomal Disease Treatment Product Solution and Service
3.5 Date of Enter into Lysosomal Disease Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Lysosomal Disease Treatment Historic Market Size by Type (2015-2020)
4.2 Global Lysosomal Disease Treatment Forecasted Market Size by Type (2021-2026)

5 LYSOSOMAL DISEASE TREATMENT BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Lysosomal Disease Treatment Market Size by Application (2015-2020)
5.2 Global Lysosomal Disease Treatment Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Lysosomal Disease Treatment Market Size (2015-2020)
6.2 Lysosomal Disease Treatment Key Players in North America (2019-2020)
6.3 North America Lysosomal Disease Treatment Market Size by Type (2015-2020)
6.4 North America Lysosomal Disease Treatment Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Lysosomal Disease Treatment Market Size (2015-2020)
7.2 Lysosomal Disease Treatment Key Players in Europe (2019-2020)
7.3 Europe Lysosomal Disease Treatment Market Size by Type (2015-2020)
7.4 Europe Lysosomal Disease Treatment Market Size by Application (2015-2020)

8 CHINA

8.1 China Lysosomal Disease Treatment Market Size (2015-2020)
8.2 Lysosomal Disease Treatment Key Players in China (2019-2020)
8.3 China Lysosomal Disease Treatment Market Size by Type (2015-2020)
8.4 China Lysosomal Disease Treatment Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Lysosomal Disease Treatment Market Size (2015-2020)
9.2 Lysosomal Disease Treatment Key Players in Japan (2019-2020)
9.3 Japan Lysosomal Disease Treatment Market Size by Type (2015-2020)
9.4 Japan Lysosomal Disease Treatment Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Lysosomal Disease Treatment Market Size (2015-2020)
10.2 Lysosomal Disease Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Lysosomal Disease Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Lysosomal Disease Treatment Market Size by Application (2015-2020)

11 INDIA

11.1 India Lysosomal Disease Treatment Market Size (2015-2020)
11.2 Lysosomal Disease Treatment Key Players in India (2019-2020)
11.3 India Lysosomal Disease Treatment Market Size by Type (2015-2020)
11.4 India Lysosomal Disease Treatment Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Lysosomal Disease Treatment Market Size (2015-2020)
12.2 Lysosomal Disease Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Lysosomal Disease Treatment Market Size by Type (2015-2020)
12.4 Central & South America Lysosomal Disease Treatment Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Astellas Pharma
  13.1.1 Astellas Pharma Company Details
  13.1.2 Astellas Pharma Business Overview and Its Total Revenue
  13.1.3 Astellas Pharma Lysosomal Disease Treatment Introduction
  13.1.4 Astellas Pharma Revenue in Lysosomal Disease Treatment Business (2015-2020))
  13.1.5 Astellas Pharma Recent Development
13.2 Astrazeneca
  13.2.1 Astrazeneca Company Details
  13.2.2 Astrazeneca Business Overview and Its Total Revenue
  13.2.3 Astrazeneca Lysosomal Disease Treatment Introduction
  13.2.4 Astrazeneca Revenue in Lysosomal Disease Treatment Business (2015-2020)
  13.2.5 Astrazeneca Recent Development
13.3 Actelion Pharmaceuticals Ltd.
  13.3.1 Actelion Pharmaceuticals Ltd. Company Details
  13.3.2 Actelion Pharmaceuticals Ltd. Business Overview and Its Total Revenue
  13.3.3 Actelion Pharmaceuticals Ltd. Lysosomal Disease Treatment Introduction
  13.3.4 Actelion Pharmaceuticals Ltd. Revenue in Lysosomal Disease Treatment Business (2015-2020)
  13.3.5 Actelion Pharmaceuticals Ltd. Recent Development
13.4 Eli Lilly and Co.
  13.4.1 Eli Lilly and Co. Company Details
  13.4.2 Eli Lilly and Co. Business Overview and Its Total Revenue
  13.4.3 Eli Lilly and Co. Lysosomal Disease Treatment Introduction
  13.4.4 Eli Lilly and Co. Revenue in Lysosomal Disease Treatment Business (2015-2020)
  13.4.5 Eli Lilly and Co. Recent Development
13.5 Merck & Co.
  13.5.1 Merck & Co. Company Details
  13.5.2 Merck & Co. Business Overview and Its Total Revenue
  13.5.3 Merck & Co. Lysosomal Disease Treatment Introduction
  13.5.4 Merck & Co. Revenue in Lysosomal Disease Treatment Business (2015-2020)
  13.5.5 Merck & Co. Recent Development
13.6 Novo Nordisk A/S
  13.6.1 Novo Nordisk A/S Company Details
  13.6.2 Novo Nordisk A/S Business Overview and Its Total Revenue
  13.6.3 Novo Nordisk A/S Lysosomal Disease Treatment Introduction
  13.6.4 Novo Nordisk A/S Revenue in Lysosomal Disease Treatment Business (2015-2020)
  13.6.5 Novo Nordisk A/S Recent Development
13.7 Shire
  13.7.1 Shire Company Details
  13.7.2 Shire Business Overview and Its Total Revenue
  13.7.3 Shire Lysosomal Disease Treatment Introduction
  13.7.4 Shire Revenue in Lysosomal Disease Treatment Business (2015-2020)
  13.7.5 Shire Recent Development
13.8 Pfizer
  13.8.1 Pfizer Company Details
  13.8.2 Pfizer Business Overview and Its Total Revenue
  13.8.3 Pfizer Lysosomal Disease Treatment Introduction
  13.8.4 Pfizer Revenue in Lysosomal Disease Treatment Business (2015-2020)
  13.8.5 Pfizer Recent Development
13.9 Sanofi
  13.9.1 Sanofi Company Details
  13.9.2 Sanofi Business Overview and Its Total Revenue
  13.9.3 Sanofi Lysosomal Disease Treatment Introduction
  13.9.4 Sanofi Revenue in Lysosomal Disease Treatment Business (2015-2020)
  13.9.5 Sanofi Recent Development
13.10 BioMarin
  13.10.1 BioMarin Company Details
  13.10.2 BioMarin Business Overview and Its Total Revenue
  13.10.3 BioMarin Lysosomal Disease Treatment Introduction
  13.10.4 BioMarin Revenue in Lysosomal Disease Treatment Business (2015-2020)
  13.10.5 BioMarin Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Lysosomal Disease Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Lysosomal Disease Treatment Revenue
Table 3. Ranking of Global Top Lysosomal Disease Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Lysosomal Disease Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Hematopoietic Stem Cell Transplantation
Table 6. Key Players of Enzyme Replacement Therapy
Table 7. Key Players of Substrate Reduction
Table 8. Key Players of Chaperone Therapies
Table 9. COVID-19 Impact Global Market: (Four Lysosomal Disease Treatment Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Lysosomal Disease Treatment Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Lysosomal Disease Treatment Players to Combat Covid-19 Impact
Table 14. Global Lysosomal Disease Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Lysosomal Disease Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Lysosomal Disease Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Lysosomal Disease Treatment Market Share by Regions (2015-2020)
Table 18. Global Lysosomal Disease Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Lysosomal Disease Treatment Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Lysosomal Disease Treatment Market Growth Strategy
Table 24. Main Points Interviewed from Key Lysosomal Disease Treatment Players
Table 25. Global Lysosomal Disease Treatment Revenue by Players (2015-2020) (Million US$)
Table 26. Global Lysosomal Disease Treatment Market Share by Players (2015-2020)
Table 27. Global Top Lysosomal Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Lysosomal Disease Treatment as of 2019)
Table 28. Global Lysosomal Disease Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Lysosomal Disease Treatment Product Solution and Service
Table 31. Date of Enter into Lysosomal Disease Treatment Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Lysosomal Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 34. Global Lysosomal Disease Treatment Market Size Share by Type (2015-2020)
Table 35. Global Lysosomal Disease Treatment Revenue Market Share by Type (2021-2026)
Table 36. Global Lysosomal Disease Treatment Market Size Share by Application (2015-2020)
Table 37. Global Lysosomal Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 38. Global Lysosomal Disease Treatment Market Size Share by Application (2021-2026)
Table 39. North America Key Players Lysosomal Disease Treatment Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Lysosomal Disease Treatment Market Share (2019-2020)
Table 41. North America Lysosomal Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 42. North America Lysosomal Disease Treatment Market Share by Type (2015-2020)
Table 43. North America Lysosomal Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 44. North America Lysosomal Disease Treatment Market Share by Application (2015-2020)
Table 45. Europe Key Players Lysosomal Disease Treatment Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Lysosomal Disease Treatment Market Share (2019-2020)
Table 47. Europe Lysosomal Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Lysosomal Disease Treatment Market Share by Type (2015-2020)
Table 49. Europe Lysosomal Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Lysosomal Disease Treatment Market Share by Application (2015-2020)
Table 51. China Key Players Lysosomal Disease Treatment Revenue (2019-2020) (Million US$)
Table 52. China Key Players Lysosomal Disease Treatment Market Share (2019-2020)
Table 53. China Lysosomal Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 54. China Lysosomal Disease Treatment Market Share by Type (2015-2020)
Table 55. China Lysosomal Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 56. China Lysosomal Disease Treatment Market Share by Application (2015-2020)
Table 57. Japan Key Players Lysosomal Disease Treatment Revenue (2019-2020) (Million US$)
Table 58. Japan Key Players Lysosomal Disease Treatment Market Share (2019-2020)
Table 59. Japan Lysosomal Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 60. Japan Lysosomal Disease Treatment Market Share by Type (2015-2020)
Table 61. Japan Lysosomal Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 62. Japan Lysosomal Disease Treatment Market Share by Application (2015-2020)
Table 63. Southeast Asia Key Players Lysosomal Disease Treatment Revenue (2019-2020) (Million US$)
Table 64. Southeast Asia Key Players Lysosomal Disease Treatment Market Share (2019-2020)
Table 65. Southeast Asia Lysosomal Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 66. Southeast Asia Lysosomal Disease Treatment Market Share by Type (2015-2020)
Table 67. Southeast Asia Lysosomal Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 68. Southeast Asia Lysosomal Disease Treatment Market Share by Application (2015-2020)
Table 69. India Key Players Lysosomal Disease Treatment Revenue (2019-2020) (Million US$)
Table 70. India Key Players Lysosomal Disease Treatment Market Share (2019-2020)
Table 71. India Lysosomal Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 72. India Lysosomal Disease Treatment Market Share by Type (2015-2020)
Table 73. India Lysosomal Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 74. India Lysosomal Disease Treatment Market Share by Application (2015-2020)
Table 75. Central & South America Key Players Lysosomal Disease Treatment Revenue (2019-2020) (Million US$)
Table 76. Central & South America Key Players Lysosomal Disease Treatment Market Share (2019-2020)
Table 77. Central & South America Lysosomal Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 78. Central & South America Lysosomal Disease Treatment Market Share by Type (2015-2020)
Table 79. Central & South America Lysosomal Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 80. Central & South America Lysosomal Disease Treatment Market Share by Application (2015-2020)
Table 81. Astellas Pharma Company Details
Table 82. Astellas Pharma Business Overview
Table 83. Astellas Pharma Product
Table 84. Astellas Pharma Revenue in Lysosomal Disease Treatment Business (2015-2020) (Million US$)
Table 85. Astellas Pharma Recent Development
Table 86. Astrazeneca Company Details
Table 87. Astrazeneca Business Overview
Table 88. Astrazeneca Product
Table 89. Astrazeneca Revenue in Lysosomal Disease Treatment Business (2015-2020) (Million US$)
Table 90. Astrazeneca Recent Development
Table 91. Actelion Pharmaceuticals Ltd. Company Details
Table 92. Actelion Pharmaceuticals Ltd. Business Overview
Table 93. Actelion Pharmaceuticals Ltd. Product
Table 94. Actelion Pharmaceuticals Ltd. Revenue in Lysosomal Disease Treatment Business (2015-2020) (Million US$)
Table 95. Actelion Pharmaceuticals Ltd. Recent Development
Table 96. Eli Lilly and Co. Company Details
Table 97. Eli Lilly and Co. Business Overview
Table 98. Eli Lilly and Co. Product
Table 99. Eli Lilly and Co. Revenue in Lysosomal Disease Treatment Business (2015-2020) (Million US$)
Table 100. Eli Lilly and Co. Recent Development
Table 101. Merck & Co. Company Details
Table 102. Merck & Co. Business Overview
Table 103. Merck & Co. Product
Table 104. Merck & Co. Revenue in Lysosomal Disease Treatment Business (2015-2020) (Million US$)
Table 105. Merck & Co. Recent Development
Table 106. Novo Nordisk A/S Company Details
Table 107. Novo Nordisk A/S Business Overview
Table 108. Novo Nordisk A/S Product
Table 109. Novo Nordisk A/S Revenue in Lysosomal Disease Treatment Business (2015-2020) (Million US$)
Table 110. Novo Nordisk A/S Recent Development
Table 111. Shire Company Details
Table 112. Shire Business Overview
Table 113. Shire Product
Table 114. Shire Revenue in Lysosomal Disease Treatment Business (2015-2020) (Million US$)
Table 115. Shire Recent Development
Table 116. Pfizer Business Overview
Table 117. Pfizer Product
Table 118. Pfizer Company Details
Table 119. Pfizer Revenue in Lysosomal Disease Treatment Business (2015-2020) (Million US$)
Table 120. Pfizer Recent Development
Table 121. Sanofi Company Details
Table 122. Sanofi Business Overview
Table 123. Sanofi Product
Table 124. Sanofi Revenue in Lysosomal Disease Treatment Business (2015-2020) (Million US$)
Table 125. Sanofi Recent Development
Table 126. BioMarin Company Details
Table 127. BioMarin Business Overview
Table 128. BioMarin Product
Table 129. BioMarin Revenue in Lysosomal Disease Treatment Business (2015-2020) (Million US$)
Table 130. BioMarin Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Lysosomal Disease Treatment Market Share by Type: 2020 VS 2026
Figure 2. Hematopoietic Stem Cell Transplantation Features
Figure 3. Enzyme Replacement Therapy Features
Figure 4. Substrate Reduction Features
Figure 5. Chaperone Therapies Features
Figure 6. Global Lysosomal Disease Treatment Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Stem Cell Transplant Center Case Studies
Figure 10. Research Organizations Case Studies
Figure 11. Others Case Studies
Figure 12. Lysosomal Disease Treatment Report Years Considered
Figure 13. Global Lysosomal Disease Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Lysosomal Disease Treatment Market Share by Regions: 2020 VS 2026
Figure 15. Global Lysosomal Disease Treatment Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Lysosomal Disease Treatment Market Share by Players in 2019
Figure 18. Global Top Lysosomal Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Lysosomal Disease Treatment as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Lysosomal Disease Treatment Revenue in 2019
Figure 20. North America Lysosomal Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Lysosomal Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Lysosomal Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Lysosomal Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Lysosomal Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Lysosomal Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Lysosomal Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Astellas Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Astellas Pharma Revenue Growth Rate in Lysosomal Disease Treatment Business (2015-2020)
Figure 29. Astrazeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Astrazeneca Revenue Growth Rate in Lysosomal Disease Treatment Business (2015-2020)
Figure 31. Actelion Pharmaceuticals Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Actelion Pharmaceuticals Ltd. Revenue Growth Rate in Lysosomal Disease Treatment Business (2015-2020)
Figure 33. Eli Lilly and Co. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Eli Lilly and Co. Revenue Growth Rate in Lysosomal Disease Treatment Business (2015-2020)
Figure 35. Merck & Co. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Merck & Co. Revenue Growth Rate in Lysosomal Disease Treatment Business (2015-2020)
Figure 37. Novo Nordisk A/S Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Novo Nordisk A/S Revenue Growth Rate in Lysosomal Disease Treatment Business (2015-2020)
Figure 39. Shire Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Shire Revenue Growth Rate in Lysosomal Disease Treatment Business (2015-2020)
Figure 41. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Pfizer Revenue Growth Rate in Lysosomal Disease Treatment Business (2015-2020)
Figure 43. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Sanofi Revenue Growth Rate in Lysosomal Disease Treatment Business (2015-2020)
Figure 45. BioMarin Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. BioMarin Revenue Growth Rate in Lysosomal Disease Treatment Business (2015-2020)
Figure 47. Bottom-up and Top-down Approaches for This Report
Figure 48. Data Triangulation
Figure 49. Key Executives Interviewed